Hemophilia without prophylaxis: Assessment of joint range of

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B - ScienceDirect

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies - ScienceDirect

Hemophilia A Patients' Joint Health Improved by Eloctate, Study Shows

Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers. - Document - Gale OneFile: Health and Medicine

Considerations for shared decision management in previously untreated patients with hemophilia A or B - Jan Astermark, Jan Blatný, Christoph Königs, Cédric Hermans, Victor Jiménez-Yuste, Daniel P. Hart, 2023

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults - Research and Practice in Thrombosis

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study - Matino - 2022 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library

Frontiers Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A

Assess joint health, Hemophilia Treatment

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

PDF) Haemophilia and joint disease: pathophysiology, evaluation and management